Decitabine in myelodysplastic syndromes and chronic myelomonocytic leukemia: Argentinian/South Korean multi-institutional clinical experience

Leukemia and Lymphoma

Volumn 51, Issue 12, 2010, Pages 2250-2257

  Iastrebner, Marcelo ^a   Jang, Jun Ho ^b   Nucifora, Elsa ^c   Kim, Kihyun ^b   Sackmann, Federico ^d   Kim, Dong Hwan ^b   Orlando, Sergio ^e   Jung, Chul Won ^b   Basquiera, Ana ^f   Klein, Graciela ^e   Santini, Fernando ^g   Bernard, Haydee I ^h   Korin, Jorge ⁱ   Taborda, Gustavo ^j  

^a San Luis Medical Center   (Argentina)

^b Sungkyunkwan University School of Medicine   (South Korea)

^c HOSPITAL ITALIANO DE BUENOS AIRES   (Argentina)

^d Hematology   (Argentina)

^e Hospital Prof Rodolfo Rossi La Plata   (Argentina)

^f HOSPITAL PRIVADO   (Argentina)

^g HOSPITAL PRIVADO DE COMUNIDAD   (Argentina)

^h Hospital Dr Ramon Madariaga   (Argentina)

ⁱ Consultorios Hematológicos ^*  (Argentina)

^j Policlinico Modelo   (Argentina)

more..

Author keywords

chronic myelomonocytic leukemia; Decitabine; myelodysplastic syndromes

Indexed keywords

5 AZA 2' DEOXYCYTIDINE;

ADULT; AGED; ALLOGENEIC STEM CELL TRANSPLANTATION; ARGENTINA; ARTICLE; ASTHENIA; BLEEDING; BONE MARROW; CANCER SURVIVAL; CHRONIC MYELOMONOCYTIC LEUKEMIA; CLINICAL TRIAL; DRUG EFFICACY; DRUG SAFETY; EOSINOPHILIA; FATIGUE; FEMALE; FEVER; HUMAN; LEUKEMIA RELAPSE; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; MYELODYSPLASTIC SYNDROME; NEUTROPENIA; PRIORITY JOURNAL; REFRACTORY ANEMIA WITH EXCESS BLASTS; REFRACTORY CYTOPENIA WITH MULTILINEAGE DYSPLASIA; REFRACTORY CYTOPENIA WITH MULTILINEAGE DYSPLASIA AND RINGED SIDEROBLASTS; SOUTH KOREA; THROMBOCYTOPENIA; TREATMENT RESPONSE;

ADULT; AGED; AGED, 80 AND OVER; ANTIMETABOLITES, ANTINEOPLASTIC; ARGENTINA; AZACITIDINE; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; INJECTIONS, INTRAVENOUS; LEUKEMIA, MYELOMONOCYTIC, CHRONIC; MALE; MIDDLE AGED; MYELODYSPLASTIC SYNDROMES; REMISSION INDUCTION; REPUBLIC OF KOREA; SURVIVAL ANALYSIS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 78650058272     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.3109/10428194.2010.524324     Document Type: Article

References (28)

1. Nimer SD. Myelodysplastic syndromes. Blood 2008;111: 4841-4851.
2. Heaney ML, Golde DW. Myelodysplasia. N Engl J Med 1999;340:1649-1660.
3. Mufti GJ, Chen TL. Changing the treatment paradigm in myelodysplastic syndromes. Cancer Control 2008;15(Suppl.): 14-28.
4. Fenaux P. Myelodysplastic syndromes: from pathogenesis and prognosis to treatment. Semin Hematol 2004;41(Suppl. 4): 6-12.
5. Ruter B, Wijermans PW, Lubbert M. DNA methylation as a therapeutic target in hematologic disorders: recent results in older patients with myelodysplasia and acute myeloid leukemia. Int J Hematol 2004;80:128-135.
6. Issa JP, Garcia-Manero G, Giles FJ, et al. Phase 1 study of low-dose prolonged exposure schedules of the hypomethylating agent 5-aza-20-deoxycytidine (decitabine) in hematopoietic malignancies. Blood 2004;103:1635-1640.
7. Issa JP, Gharibyan V, Cortes J, et al. Phase II study of lowdose decitabine in patients with chronic myelogenous leukemia resistant to imatinib mesylate. J Clin Oncol 2005;23: 3948-3956. (Pubitemid 46218698)
8. Leone G, Teofili L, Voso MT, Lubbert M. DNA methylation and demethylating drugs in myelodysplastic syndromes and secondary leukemias. Haematologica 2002;87:1324-1341.
9. Wijermans PW, Krulder JW, Huijgens PC, Neve P. Continuous infusion of low-dose 5-aza-20-deoxycytidine in elderly patients with high-risk myelodysplastic syndrome. Leukemia 1997;11:1-5. (Pubitemid 27065040)
10. Wijermans P, Lubbert M, Verhoef G, et al. Low-dose 5-aza- 20-deoxycytidine, a DNA hypomethylating agent, for the treatment of high-risk myelodysplastic syndrome: a multicenter phase II study in elderly patients. J Clin Oncol 2000;18: 956-962.
11. Saba HI, Wijermans PW. Decitabine in myelodysplastic syndromes. Semin Hematol 2005;42(Suppl. 2): S23-S31.
12. Kantarjian H, Issa JP, Rosenfeld CS, et al. Decitabine improves patient outcomes in myelodysplastic syndromes: results of a phase III randomized study. Cancer 2006;106: 1794-1803.
13. Cheson BD, Bennett JM, Kantarjian H, et al. Report of an international working group to standardize response criteria for myelodysplastic syndromes. Blood 2000;96:3671-3674.
14. Ruter B, Wijermans PW, Lubbert M. Superiority of prolonged low-dose azanucleoside administration? Results of 5-aza-20- deoxycytidine retreatment in high-risk myelodysplasia patients. Cancer 2006;106:1744-1750.
15. Jones PA, Taylor SM. Cellular differentiation, cytidine analogs and DNA methylation. Cell 1980;20:85-93.
16. Kantarjian H, Oki Y, Garcia-Manero G, et al. Results of a randomized study of 3 schedules of low-dose decitabine in higher-risk myelodysplastic syndrome and chronic myelomonocytic leukemia. Blood 2007;109:52-57.
17. Steensma DP, Baer MR, Slack JL, et al. Multicenter study of decitabine administered daily for 5 days every 4 weeks to adults with myelodysplastic syndromes: the alternative dosing for outpatient treatment (ADOPT) trial. J Clin Oncol 2009;27:3842-3848.
18. Borthakur G, Ahdab SE, Ravandi F, et al. Activity of decitabine in patients with myelodysplastic syndrome previously treated with azacitidine. Leuk Lymphoma 2008;49: 690-695.
19. Bennett JM, Catovsky D, Daniel MT, et al. Proposals for the classification of the myelodysplastic syndromes. Br J Haematol 1982;51:189-199.
20. Onida F, Kantarjian HM, Smith TL, et al. Prognostic factors and scoring systems in chronic myelomonocytic leukemia: a retrospective analysis of 213 patients. Blood 2002;99:840-849.
21. Cheson BD, Greenberg PL, Bennett JM, et al. Clinical application and proposal for modification of the International Working Group (IWG) response criteria in myelodysplasia. Blood 2006;108:419-425.
22. Greenberg P, Cox C, LeBeau MM, et al. International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood 1997;89:2079-2088.
23. Aribi A, Borthakur G, Ravandi F, et al. Activity of decitabine, a hypomethylating agent, in chronic myelomonocytic leukemia. Cancer 2007;109:713-717.
24. Wijermans PW, Ruter B, Baer MR, Slack JL, Saba HI, Lubbert M. Efficacy of decitabine in the treatment of patients with chronic myelomonocytic leukemia (CMML). Leuk Res 2008;32:587-591.
25. Vardiman JW, Thiele J, Arber DA, et al. The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes. Blood 2009;114:937-951.
26. Kantarjian HM, OBrien S, Shan J, et al. Update of the decitabine experience in higher risk myelodysplastic syndrome and analysis of prognostic factors associated with outcome. Cancer 2007;109:265-273.
27. Kantarjian H, Giles F, List A, et al. The incidence and impact of thrombocytopenia in myelodysplastic syndromes. Cancer 2007;109:1705-1714. (Pubitemid 46668530)
28. Scott BL, Park JY, Deeg HJ, et al. Pretransplant neutropenia is associated with poor-risk cytogenetic features and increased infection-related mortality in patients with myelodysplastic syndromes. Biol Blood Marrow Transplant 2008;14: 799-806.